CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has completed enrollment.In Sub-studies 1 and 2...
Phase 1, Phase 2
Pittsburgh, Pennsylvania, United States and 55 other locations
with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute myeloid leukemia...
Phase 3
Pittsburgh, Pennsylvania, United States and 108 other locations
Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib ...
Phase 2
Pittsburgh, Pennsylvania, United States and 43 other locations
chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...
Phase 2
Pittsburgh, Pennsylvania, United States and 110 other locations
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia...
Phase 1, Phase 2
Pittsburgh, Pennsylvania, United States and 25 other locations
(CPX-351) works in treating patients with secondary acute myeloid leukemia who are younger than 60 years old. Drugs used in chemotherapy, su...
Phase 2
Pittsburgh, Pennsylvania, United States and 3 other locations
Acute Myeloid Leukaemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections). Successful...
Phase 3
Pittsburgh, Pennsylvania, United States and 171 other locations
This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in...
Phase 3
Pittsburgh, Pennsylvania, United States and 160 other locations
safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia...
Phase 1, Phase 2
Pittsburgh, Pennsylvania, United States and 34 other locations
of the study is to characterize safety and tolerability of cusatuzumab in combination with various therapies used to treat acute myeloid leukemia...
Phase 1
Pittsburgh, Pennsylvania, United States and 22 other locations
Clinical trials
Research sites
Resources
Legal